Eligible studies compared any multi-domain telephone-based assessment ofĬognition to the face-to-face diagnostic evaluation. Two researchers independently screened articlesĪnd extracted data. Methods: Five multidisciplinary databases were searched. Objective: We sought to determine the accuracy of telephone-based screening for the identification ofĭementia or Mild Cognitive Impairment (MCI). In terms of test burden, economic and opportunity cost. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.Background: Telephone-based cognitive assessments may be preferable to in-person testing The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). This is particularly important when the recommended agent is a new and/or infrequently employed drug. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. Usage and distribution for commercial purposes requires written permission. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). It is necessary to diagnose in an assertive and timely manner in order to generate functional neurorehabilitation plans in people diagnosed with CBD, with the main objective of positively impacting quality of life, at the individual, family, and social level. It was found that the patient presented neurocognitive alterations of the executive type (frontal lobe) such as decision making, planning, inhibition and operative memory, correlated with a severe alteration in her basic, instrumental and advanced activities of daily life, with a high risk factor for developing dementia. The patient presented conciliation insomnia, gait disturbances, and severe neurocognitive deficit, especially in executive functions, immediate verbal memory, and visuospatial functioning. Initially, she was diagnosed with Alzheimer’s disease and Lewy body dementia, finding that she had no characteristic signs and symptoms of these pathologies. Participant was a 70-year-old female patient, single she presented progressive memory loss of an immediate verbal nature. We identified neurocognitive impairment and neuropsychiatric symptoms in a patient diagnosed with CBD. Corticobasal degeneration (CBD) is a pathology of low incidence and prevalence worldwide it is accompanied by symptoms such as dystonia, rigid akinetic syndrome (bradykinesia), gait disturbances, neurological deterioration associated with severe cortical subcortical atrophy, and progressive to moderate to severe neurocognitive deficits, especially in immediate verbal memory and dorsolateral or dysexecutive syndrome.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |